Improvement in Quality of Life (QoL) in COPD patients treated with Roflumilast as assessed by the Clinical COPD Questionnaire (CCQ)

Background: Substantial data on patient reported outcome such as Quality of Life (QoL) in COPD are lacking for the novel anti-inflammatory agent roflumilast. This 6-month non-interventional study investigated the effects of once-daily 500 µg roflumilast on QoL in routine daily medical practice by means of the Clinical COPD Questionnaire (CCQ). Methods: A total of 3597 patients (intention-to-treat, ITT; 65% male; mean age: 65.5 ± 9.9 years; mean BMI 27.3 ± 5.7 kg/m2) were enrolled and treated with roflumilast 500 µg once daily for up to 6 months in 739 study centres in Germany. Patients with severe COPD (post-bro…